Search

Ascidian Therapeutics' CEO discusses today's collaboration with Roche on the company's RNA exon editing technology for neurological conditions
Mike Ehlers describes how this $42M upfront and up to $1.8B in potential milestones deal is focused on neurological conditions, how RNA...
Jun 18, 2024

The Science Behind the News: Ascidian Therapeutics' IND is cleared for an RNA exon editing program against Stargardt disease
Ascidian Interim President & CEO Mike Ehlers explains the scientific concept of RNA exon editing
Jan 29, 2024